Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06034743 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
A Phase 3 study of Uncontrolled Hypertension and Resistant Hypertension, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 796
- Enrollment target
- 20
- Study locations
NCT06034743: Completed Phase 3 study of Uncontrolled Hypertension and Resistant Hypertension, sponsored by AstraZeneca.
NCT06034743 is a Phase 3 study of Uncontrolled Hypertension and Resistant Hypertension that has completed, run by AstraZeneca. The registered enrollment target is 796 participants, above the 685-participant average among 10 other Uncontrolled Hypertension trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06034743, a Phase 3 study of Uncontrolled Hypertension and Resistant Hypertension, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 796 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).
Primary Outcome
To assess the effect of 2 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12. All available measurements were included, and missing data were multiply imputed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baxdrostat
Study Locations (20)
California
- Research Site - Fresno
- Research Site - Lincoln
- Research Site - Orange
- Research Site - Rancho Cucamonga
- Research Site - Stanford
Arizona
- Research Site - Scottsdale
- Research Site - Sun City West
- Research Site - Surprise
Florida
- Research Site - Clearwater
- Research Site - Jacksonville
- Research Site - Port Orange
Georgia
- Research Site - Atlanta
- Research Site - Decatur
Alabama
- Research Site - Saraland
Arkansas
- Research Site - Little Rock
Connecticut
- Research Site - New Haven
Illinois
- Research Site - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 796 participants |
| Start Date | 2023-11-22 |
| Est. Completion | 2025-10-10 |
| Phase | Phase 3 |
What the finished NCT06034743 record still lists
NCT06034743 is an interventional study that assigns participants to a tested intervention. The registered 796 participants enrollment target is mid-sized for trials with a published cap, above the 685-participant average among 10 other Uncontrolled Hypertension trials with a reported enrollment target (16% higher).
The record links to 2 conditions, with Uncontrolled Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06034743 names 20 study sites across 11 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06034743 about?
NCT06034743 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension". This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 partici...
What is the current status of trial NCT06034743?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 796 participants. The study started on 2023-11-22. Estimated completion is 2025-10-10.
What conditions does trial NCT06034743 study?
This clinical trial studies the following conditions: Uncontrolled Hypertension, Resistant Hypertension.
What interventions are being tested in trial NCT06034743?
The interventions under investigation include: Placebo (DRUG), Baxdrostat (DRUG).
Who is sponsoring clinical trial NCT06034743?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06034743 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uncontrolled Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06034743's enrollment target sits among peer trials
796 4th of 10 higher than 7 of 10 other Uncontrolled Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uncontrolled Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity
RECRUITING · NA
-
Renal Pelvic Denervation Pilot Trial
RECRUITING · NA
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Wearable Evaluation of Ambulatory Readings for Blood Pressure
RECRUITING · NA
-
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Remote Hypertension Management for Black Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT06051058 · 798 participants · NA
Care Transitions App for Patients With Multiple Chronic Conditions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI